20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Key technology for a future without fossil fuelsIn June and July 2025, catalyst researcher Nico Fischer spent some time at HZB. It was his sabbatical, he was relieved of his duties as Director of the Catalysis Institute in Cape Town for several months and was able to focus on research only. His institute is collaborating with HZB on two projects that aim to develop environmentally friendly alternatives using innovative catalyst technologies. The questions were asked by Antonia Rötger, HZB.
- 5000th patient treated with protons for eye tumoursFor more than 20 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
- Iridium-free catalysts for acid water electrolysis investigatedHydrogen will play an important role, both as a fuel and as a raw material for industry. However, in order to produce relevant quantities of hydrogen, water electrolysis must become feasible on a multi-gigawatt scale. One bottleneck is the catalysts required, with iridium in particular being an extremely rare element. An international collaboration has therefore investigated iridium-free catalysts for acidic water electrolysis based on the element cobalt. Through investigations with various methods, among them experiments at the LiXEdrom at the BESSY II X-ray source in Berlin, they were able to elucidate processes that take place during water electrolysis in a cobalt-iron-lead oxide material as the anode. The study is published in Nature Energy.